vs
Amphastar Pharmaceuticals, Inc.（AMPH）与WESBANCO INC（WSBC）财务数据对比。点击上方公司名可切换其他公司
WESBANCO INC的季度营收约是Amphastar Pharmaceuticals, Inc.的1.4倍（$257.2M vs $183.1M），WESBANCO INC净利率更高（34.5% vs 13.3%，领先21.1%），过去两年WESBANCO INC的营收复合增速更高（31.9% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
WesBanco是一家总部位于美国西弗吉尼亚州惠灵的银行控股公司，业务覆盖广泛，目前在西弗吉尼亚州、俄亥俄州、宾夕法尼亚州西部、肯塔基州、马里兰州及印第安纳州南部拥有超过200家营业网点，为当地客户提供多元金融服务。
AMPH vs WSBC — 直观对比
营收规模更大
WSBC
是对方的1.4倍
$183.1M
净利率更高
WSBC
高出21.1%
13.3%
两年增速更快
WSBC
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $257.2M |
| 净利润 | $24.4M | $88.6M |
| 毛利率 | 46.8% | — |
| 营业利润率 | 19.4% | — |
| 净利率 | 13.3% | 34.5% |
| 营收同比 | -1.8% | — |
| 净利润同比 | -35.7% | 54.4% |
| 每股收益（稀释后） | $0.51 | $0.88 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHWSBC
| Q1 26 | — | $257.2M | ||
| Q4 25 | $183.1M | $265.6M | ||
| Q3 25 | $191.8M | $261.6M | ||
| Q2 25 | $174.4M | $260.7M | ||
| Q1 25 | $170.5M | $193.2M | ||
| Q4 24 | $186.5M | $162.9M | ||
| Q3 24 | $191.2M | $150.8M | ||
| Q2 24 | $182.4M | $147.9M |
净利润AMPHWSBC
| Q1 26 | — | $88.6M | ||
| Q4 25 | $24.4M | $91.1M | ||
| Q3 25 | $17.4M | $83.6M | ||
| Q2 25 | $31.0M | $57.4M | ||
| Q1 25 | $25.3M | $-9.0M | ||
| Q4 24 | $38.0M | $49.6M | ||
| Q3 24 | $40.4M | $37.3M | ||
| Q2 24 | $37.9M | $28.9M |
毛利率AMPHWSBC
| Q1 26 | — | — | ||
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — |
营业利润率AMPHWSBC
| Q1 26 | — | — | ||
| Q4 25 | 19.4% | 43.2% | ||
| Q3 25 | 13.2% | 39.5% | ||
| Q2 25 | 24.2% | 27.2% | ||
| Q1 25 | 21.9% | -5.0% | ||
| Q4 24 | 24.2% | 38.0% | ||
| Q3 24 | 29.8% | 29.7% | ||
| Q2 24 | 30.3% | 23.7% |
净利率AMPHWSBC
| Q1 26 | — | 34.5% | ||
| Q4 25 | 13.3% | 34.3% | ||
| Q3 25 | 9.0% | 31.9% | ||
| Q2 25 | 17.8% | 22.0% | ||
| Q1 25 | 14.8% | -4.7% | ||
| Q4 24 | 20.4% | 30.5% | ||
| Q3 24 | 21.1% | 24.7% | ||
| Q2 24 | 20.8% | 19.5% |
每股收益（稀释后）AMPHWSBC
| Q1 26 | — | $0.88 | ||
| Q4 25 | $0.51 | $0.97 | ||
| Q3 25 | $0.37 | $0.84 | ||
| Q2 25 | $0.64 | $0.57 | ||
| Q1 25 | $0.51 | $-0.15 | ||
| Q4 24 | $0.74 | $0.72 | ||
| Q3 24 | $0.78 | $0.54 | ||
| Q2 24 | $0.73 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | — |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $4.1B |
| 总资产 | $1.6B | $27.5B |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHWSBC
| Q1 26 | — | — | ||
| Q4 25 | $282.8M | $956.1M | ||
| Q3 25 | $276.2M | $1.0B | ||
| Q2 25 | $231.8M | $1.2B | ||
| Q1 25 | $236.9M | $1.1B | ||
| Q4 24 | $221.6M | $568.1M | ||
| Q3 24 | $250.5M | $620.9M | ||
| Q2 24 | $217.8M | $486.8M |
总债务AMPHWSBC
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — |
股东权益AMPHWSBC
| Q1 26 | — | $4.1B | ||
| Q4 25 | $788.8M | $4.0B | ||
| Q3 25 | $776.7M | $4.1B | ||
| Q2 25 | $757.5M | $3.8B | ||
| Q1 25 | $751.3M | $3.8B | ||
| Q4 24 | $732.3M | $2.8B | ||
| Q3 24 | $727.7M | $2.8B | ||
| Q2 24 | $713.3M | $2.5B |
总资产AMPHWSBC
| Q1 26 | — | $27.5B | ||
| Q4 25 | $1.6B | $27.7B | ||
| Q3 25 | $1.7B | $27.5B | ||
| Q2 25 | $1.6B | $27.6B | ||
| Q1 25 | $1.6B | $27.4B | ||
| Q4 24 | $1.6B | $18.7B | ||
| Q3 24 | $1.5B | $18.5B | ||
| Q2 24 | $1.5B | $18.1B |
负债/权益比AMPHWSBC
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | — |
| 自由现金流经营现金流 - 资本支出 | $24.6M | — |
| 自由现金流率自由现金流/营收 | 13.4% | — |
| 资本支出强度资本支出/营收 | 4.5% | — |
| 现金转化率经营现金流/净利润 | 1.35× | — |
| 过去12个月自由现金流最近4个季度 | $121.2M | — |
8季度趋势，按日历期对齐
经营现金流AMPHWSBC
| Q1 26 | — | — | ||
| Q4 25 | $32.9M | $290.4M | ||
| Q3 25 | $52.6M | $116.9M | ||
| Q2 25 | $35.6M | $105.0M | ||
| Q1 25 | $35.1M | $-26.4M | ||
| Q4 24 | $29.0M | $211.0M | ||
| Q3 24 | $60.0M | $60.7M | ||
| Q2 24 | $69.1M | $18.2M |
自由现金流AMPHWSBC
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $280.0M | ||
| Q3 25 | $47.2M | $114.9M | ||
| Q2 25 | $25.0M | $98.3M | ||
| Q1 25 | $24.4M | $-30.7M | ||
| Q4 24 | $16.6M | $200.7M | ||
| Q3 24 | $46.2M | $56.9M | ||
| Q2 24 | $63.1M | $17.3M |
自由现金流率AMPHWSBC
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 105.4% | ||
| Q3 25 | 24.6% | 43.9% | ||
| Q2 25 | 14.3% | 37.7% | ||
| Q1 25 | 14.3% | -15.9% | ||
| Q4 24 | 8.9% | 123.2% | ||
| Q3 24 | 24.1% | 37.7% | ||
| Q2 24 | 34.6% | 11.7% |
资本支出强度AMPHWSBC
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 3.9% | ||
| Q3 25 | 2.8% | 0.8% | ||
| Q2 25 | 6.1% | 2.6% | ||
| Q1 25 | 6.3% | 2.2% | ||
| Q4 24 | 6.7% | 6.3% | ||
| Q3 24 | 7.2% | 2.5% | ||
| Q2 24 | 3.3% | 0.6% |
现金转化率AMPHWSBC
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | 3.19× | ||
| Q3 25 | 3.03× | 1.40× | ||
| Q2 25 | 1.15× | 1.83× | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | 4.25× | ||
| Q3 24 | 1.48× | 1.63× | ||
| Q2 24 | 1.82× | 0.63× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
WSBC
| Net Interest Income | $215.4M | 84% |
| Noninterest Income | $41.8M | 16% |
